Table 2.
Experimental details of experiments involving AT of splenocytes in mice
| Donors | Dose | Recipients | Site | n | Figure |
|---|---|---|---|---|---|
| Splenocytes from 20- to 25-week-old Ins2-CCL21 NOD mice | 10 million | 4- to 6-week-old female NOD-scid mice | IV | 12 | Fig. 3A (red) |
| Splenocytes from 20- to 25-week-old diabetic NOD mice | 10 million | 4- to 6-week-old female NOD-scid mice | IV | 3 | Fig. 3A (black) |
| Splenocytes from 20- to 25-week-old diabetic NOD mice | 10 million | 10-week-old female Ins2-CCL21 NOD mice | IV | 6 | Fig. 5A (red) |
| Splenocytes from 20- to 25-week-old diabetic NOD mice | 10 million | 10-week-old female NOD mice | IV | 5 | Fig. 5A (black) |
| Splenocytes from 20- to 25-week-old diabetic NOD mice | 10 million | 11-week-old NOD-scid mice (4 weeks after NOD islet transplantation in KD) | IV | 6 | Fig. 5C (black) |
| Splenocytes from 20- to 25-week-old diabetic NOD mice | 10 million | 11-week-old NOD-scid mice (4 weeks after Ins2-CCL21 islet transplantation in KD) | IV | 7 | Fig. 5C (red) |